Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence

Xu, Huiru; Feng, Huijing; Zhang, Weihong; Wang, Feng; Zhou, Li; Liu, Liang; Zhao, Yu; Lv, Yingge; Shi, Xiuhuan; Zhang, Junping; Ren, Xiaoyan

doi:10.1016/j.yexcr.2022.113157

Cited by 19 publications

(19 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…( 11 ) in 2014, which could reflect the local immune response and systemic inflammation in the whole human body ( 12 – 15 ). SII has been used in past studies to predict and evaluate the prognosis of various solid tumors, such as gastric cancer ( 16 , 17 ), non-small cell lung cancer ( 18 , 19 ), pancreatic cancer ( 20 ), and esophageal cancer ( 21 , 22 ). In addition, SII also has a high value for the prognosis of cardiovascular disease ( 23 – 27 ).…”

Section: Introductionmentioning

confidence: 99%

Association between SII and hepatic steatosis and liver fibrosis: A population-based study

et al. 2022

View full text Add to dashboard Cite

BackgroundThe systemic immune-inflammation index (SII) is a novel marker of inflammation, and hepatic steatosis and fibrosis are associated with inflammation. This study aimed to investigate the possible relationship between SII and hepatic steatosis and fibrosis.MethodsThe datasets from the National Health and Nutrition Examination Survey (NHANES) 2017–2020 were used in a cross-sectional investigation. Multivariate linear regression models were used to examine the linear connection between SII and controlled attenuation parameter (CAP) and liver stiffness measurement (LSM). Fitted smoothing curves and threshold effect analysis were used to describe the nonlinear relationship.ResultsThis population-based study included a total of 6,792 adults aged 18–80 years. In a multivariate linear regression analysis, a significant positive association between SII and CAP was shown [0.006 (0.001, 0.010)]. This positive association in a subgroup analysis was maintained in men [0.011 (0.004, 0.018)] but not in women. Furthermore, the association between SII and CAP was nonlinear; using a two-segment linear regression model, we found an inverted U-shaped relationship between SII and CAP with an inflection point of 687.059 (1,000 cells/µl). The results of the multiple regression analysis showed that the relationship between SII and LSM was not significant (P = 0.263).ConclusionsOur findings imply that increased SII levels are linked to hepatic steatosis, but SII is not linked to liver fibrosis. To confirm our findings, more large-scale prospective investigations are needed.

show abstract

Section: Introductionmentioning

confidence: 99%

Association between SII and hepatic steatosis and liver fibrosis: A population-based study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The types of blood counts reported are as follows: absolute eosinophil count (AEC), derived neutrophil: lymphocyte ratio (dNLR), neutrophil: lymphocyte ratio (NLR), absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute monocyte count (AMC), platelet count (PLT), monocyte: lymphocyte ratio (MLR), platelet: lymphocyte ratio (PLR), etc. Eight studies showed substantial truncation values ( 11 , 15 – 17 , 20 , 23 , 25 , 28 ). Eleven studies reported the use of receiver operating characteristic (ROC) curve analysis to calculate the optimal cutoff value ( 11 , 15 – 17 , 19 – 21 , 23 – 26 ).…”

Section: Resultsmentioning

confidence: 99%

Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis

Zhou

Du²,

Fu³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundCancer is concerning owing to its high mortality rate. Consequently, methods of prolonging the life of patients with cancer have become the primary focus of attention research. In recent years, immune checkpoint inhibitors (ICIs) have achieved good clinical efficacy as antitumor drugs; however, their severe adverse effects have made their use challenging. In order to clarify the predictors of adverse effects, scientists have conducted a series of studies. Blood counts can potentially monitor risk factors associated with the occurrence of immune-related adverse events (irAEs). Herein, a meta-analysis was performed to clarify further the guiding significance of blood counts in the clinical setting.MethodsStudies that satisfied the inclusion criteria were obtained by searching the database. Included studies were those in which irAEs had been observed, and evidence of an association between blood counts and irAEs was reported. The included ones were evaluated for quality. In addition to sensitivity analysis and subgroup analysis, a meta-analysis was performed using the odds ratio (OR) and 95% confidence interval (CI) for each study.ResultsA total of 18 articles were included in our study. The analyses were performed separately according to different blood cell count indicators. The blood cell count metrics associated with irAEs were: absolute eosinophil count, neutrophil: lymphocyte ratio, and platelet: lymphocyte ratio.ConclusionOur review and meta-analysis of studies suggest that absolute eosinophil count, neutrophil: lymphocyte ratio, and platelet: lymphocyte ratio may serve as predictors of the emergence of irAEs. Given the small number of studies focusing on the relationship between patient blood cell counts and the risk of irAEs, future studies need to further explore the mechanisms of occurrence and potential associations.

show abstract

“…The median numbers of doses of atezolizumab and bevacizumab were 5 (2-33) and 5 (2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21), respectively. The overall median PFS was 31 weeks (Figure 2a).…”

Section: Therapeutic Responsementioning

confidence: 99%

“…[9][10][11][12][13] Studies have reported that the presence of RF and thyroid autoantibodies at baseline could be associated with irAE development in patients with other types of carcinomas. 14,15 Moreover, smoking, high body mass index, history of autoimmune diseases, and use of concomitant medications such as proton pump inhibitors and nonsteroidal anti-inflammatory drugs might be also associated with irAE development. 16 However, the risk factors for irAE development in patients receiving AB therapy for u-HCC remain unclear.…”

Section: Introductionmentioning

confidence: 99%

Significance of the autoantibody assay in predicting the development of immune‐related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocellular carcinoma

Takada,

Yamashita,

Osawa

et al. 2023

Hepatology Research

View full text Add to dashboard Cite

AimAtezolizumab plus bevacizumab (AB) combination therapy is the first‐line treatment for unresectable hepatocellular carcinoma (u‐HCC). The management of immune‐related adverse events (irAEs) is an important issue associated with achieving a good therapeutic response in patients receiving AB therapy. However, few studies have reported irAE development in patients receiving AB therapy. This study focused on the the association between irAE development and autoantibodies at baseline in patients receiving AB therapy.MethodsSixty‐one patients receiving AB therapy were enrolled. For autoantibodies, the following antibodies were tested before the start of AB therapy: antinuclear antibodies, rheumatoid factor (RF), anti‐thyroglobulin antibodies, thyroid peroxidase antibodies, anti‐thyroid stimulating hormone receptor antibodies, and acetylcholine receptor antibodies. A patient was considered to have any preexisting antibodies if any of the listed antibodies were present at baseline.ResultsTen patients (16%) developed irAEs during the observation period. The irAEs included liver injury, hypothyroidism, adrenal insufficiency, adrenocorticotropic hormone deficiency, and rhabdomyolysis. Patients with irAE (n = 10) were more likely to be positive for any autoantibody (hazard ratio (HR): 3.7, p = 0.047) and RF at baseline (HR: 5.4, p = 0.035) and to achieve complete response (HR: 5.8, p = 0.027) than those without. The presence of autoantibodies at baseline was an independent factor associated with irAE development.ConclusionIn the real world, 16% of patients receiving AB therapy for u‐HCC developed irAEs. Patients with autoantibodies at baseline are at high risk of developing irAEs and require cautious follow‐up.This article is protected by copyright. All rights reserved.

show abstract

Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence

Cited by 19 publications

References 38 publications

Association between SII and hepatic steatosis and liver fibrosis: A population-based study

Association between SII and hepatic steatosis and liver fibrosis: A population-based study

Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis

Significance of the autoantibody assay in predicting the development of immune‐related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocellular carcinoma

Contact Info

Product

Resources

About